Aeterna Zentaris (AEZS) Reports Results from Phase 3 Trial for Perifosine; Data Showed No Benefit in Survival
Go back to Aeterna Zentaris (AEZS) Reports Results from Phase 3 Trial for Perifosine; Data Showed No Benefit in Survival| AETERNA ZENTARIS (NASDAQ: AEZS) | Delayed: 5.72 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.72 | 52 Week High | $15.70 | |||
| Open | $5.72 | 52 Week Low | $0.04 | |||
| Day High | $5.72 | P/E | N/A | |||
| Day Low | $5.72 | EPS | $0.00 | |||
| Volume | 148,411 | |||||
